Hochdorf Swiss Nutrition has appointed Sandro Tichelli as its next chief executive, a leadership transition that will commence at the start of 2026.
In this new role, Tichelli will succeed Ralph Siegl, who has been at the helm of the Switzerland-based infant formula and dairy ingredients producer since 2022.
The company’s board of directors expressed gratitude to Siegl for successfully guiding Hochdorf through its separation from its former parent company and the subsequent sale to AS Equity Partners in 2024.
Tichelli brings a wealth of experience, having previously held management roles at Danone in Switzerland and Germany. Most recently, he served as country manager for Switzerland and participated on the DACH region executive board.
Until Tichelli officially takes over, Oliver Banz will serve as the interim chief executive. Banz is not only a partner but also the head of portfolio management at AS Equity Partners. Additionally, he has a background as a lawyer and management consultant at McKinsey.
Upon Tichelli’s appointment, the board commented: “Following the completion of this transition phase, we aim to lead Hochdorf towards renewed international growth. We are confident that Sandro Tichelli, with his dynamic personality, extensive management experience, and deep understanding of the international food market, is the ideal CEO to achieve this.”
Tichelli remarked: “The company has excellent products, strong brands, and great potential. Together with our team, we will drive growth and strengthen Hochdorf’s position as a leading global provider of nutritional solutions.”
Founded in 1895, Hochdorf specializes in milk-based products for infants and young children, alongside other milk powders and nutritional supplements. Its notable brand includes Bimbosan.
In light of strategic challenges, the company effectively put itself up for sale in April 2024 as part of a comprehensive review of its business, aimed at refocusing its core competencies.
Hochdorf Holding commenced this strategic reassessment in 2019 following a series of profit warnings, leading to the divestment of its majority stake in the baby-food business Pharmalys and an exit from product areas such as cooking oils, flour, cereals, snacks, and fruits and vegetables.